HYFTOR™ is the first and only topical medication approved by the FDA to treat facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and children 6 years and older.
HYFTOR™ is a clear gel that contains an mTOR inhibitor.
HYFTOR™ should be applied to the skin of the face affected with angiofibroma twice daily, in the morning and at bedtime. The maximum recommended daily dosage is1:
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR.
WARNINGS AND PRECAUTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.